DRG Market Assessment 보고서

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…

Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…

Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cholangiocarcinoma patient populations, covering 171 countries and…

The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…

The treatment landscape for multiple sclerosis (MS) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (DMTs) available and more in development. The market…

Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India,…

Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…